<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01934296</url>
  </required_header>
  <id_info>
    <org_study_id>Activa PC+S</org_study_id>
    <nct_id>NCT01934296</nct_id>
  </id_info>
  <brief_title>Chronic Effects of DBS in Parkinson's Disease and Dystonia</brief_title>
  <acronym>Activa PC+S</acronym>
  <official_title>Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use an investigational device to record brain activity for&#xD;
      12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The&#xD;
      goal of the study is better understanding of brain activity in movement disorders and how&#xD;
      they relate to DBS, not to bring new devices to market.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortical and sub-cortical brain signals using Activa PC+S</measure>
    <time_frame>24 months</time_frame>
    <description>Establish whether it is possible to record a reliable cortical and subcortical brain signal using Activa PC+S.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">11</enrollment>
  <condition>Parkinson's Disease</condition>
  <condition>Isolated Dystonia</condition>
  <arm_group>
    <arm_group_label>chronic brain recording</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Activa PC+S</intervention_name>
    <description>Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation</description>
    <arm_group_label>chronic brain recording</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria(both groups):&#xD;
&#xD;
          -  Ability to give informed consent for the study&#xD;
&#xD;
          -  Movement disorder symptoms that are sufficiently severe, in spite of best medical&#xD;
             therapy, to warrant surgical implantation of deep brain stimulators according to&#xD;
             standard clinical criteria&#xD;
&#xD;
        Inclusion criteria (Isolated dystonia):&#xD;
&#xD;
          -  Age 22-75&#xD;
&#xD;
          -  Isolated dystonia that is generalized or segmental, that must affect one or - Stable&#xD;
             doses of anti-dystonia medications (such as Artane, Baclofen, or Clonopin) for at&#xD;
             least 30 days prior to baseline assessment&#xD;
&#xD;
          -  For patients with craniofacial involvement, prior treatment with botulinum toxin with&#xD;
             failure to adequately control dystonia symptoms.&#xD;
&#xD;
        Inclusion criteria (PD):&#xD;
&#xD;
          -  Age 30-75&#xD;
&#xD;
          -  Bilateral disease (Hoehn and Yahr stage 2 or greater)&#xD;
&#xD;
          -  Has been treated with levodopa/carbidopa, and with a dopamine agonist, at the maximal&#xD;
             tolerated doses as determined by a movement disorders neurologist&#xD;
&#xD;
          -  Stable doses of antiParkinsonian medications for at least 30 days prior to their&#xD;
             baseline assessment&#xD;
&#xD;
          -  Significant disability in the setting of optimal medical management by a movement&#xD;
             disorders neurologist. Disability may be due to tremor that is unresponsive to&#xD;
             medications, or to motor fluctuations&#xD;
&#xD;
          -  UPDRS-III score off medication between 20 and 60&#xD;
&#xD;
          -  Improvement of at least 30% in the baseline UPDRS-III on medication score, compared to&#xD;
             the baseline off-medication score.&#xD;
&#xD;
        Exclusion Criteria (both groups):&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  MRI showing cortical atrophy out of proportion to age&#xD;
&#xD;
          -  MRI showing focal brain lesions that could indicate a non-idiopathic movement&#xD;
             disorder,&#xD;
&#xD;
          -  Major comorbidity increasing the risk of surgery (prior stroke, severe hypertension,&#xD;
             severe diabetes, or need for chronic anticoagulation other than aspirin)&#xD;
&#xD;
          -  Inability to comply with study follow-up visits&#xD;
&#xD;
          -  Any prior intracranial surgery&#xD;
&#xD;
          -  Mood depression with a Beck depression inventory score of &gt; 17 on baseline screening&#xD;
&#xD;
          -  Significant cognitive impairment (MoCA&lt;25).&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Immunocompromised&#xD;
&#xD;
          -  Has an active infection&#xD;
&#xD;
          -  Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic - Has an&#xD;
             implanted electronic device such as a neurostimulator, cardiac pacemaker or medication&#xD;
             pump.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Starr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Surgical Movement Disorders Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Philip Starr</investigator_full_name>
    <investigator_title>Professor, Neurological Surgery</investigator_title>
  </responsible_party>
  <keyword>deep brain stimulation</keyword>
  <keyword>cortical recording</keyword>
  <keyword>neuroprosthesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

